Drugs / LAM-001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05798923 Comparator | Aug 2023 → Jul 2027 expected | pulmonary hypertension owing to lung disease and/or hypoxia | OrphAI Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05798923 ↗ |
| Known as | sirolimus | “In Part B, approximately 75 participants will receive standard of care plus LAM- 001 (inhaled sirolimus) 100 mcg, 200 mcg or placebo by oral inhalation once daily for the first...” NCT05798923 ↗ |
| Route | Inhaled | “LAM-001 (2, 100 mcg oral inhalations) once daily via a Dry Powder Inhaler (DPI)” NCT05798923 ↗ |